The purpose of this study was to compare the variability of the amplitude ratios and latencies of the electro-oculogram (EOG) light peak (LP) in three different recording conditions: Arden ratio (dark trough (DT): 12 min), modified Arden ratio (DT: 15 min) and light peak/dark baseline ratio (LP/BL: 35 min of dark adaptation). Additionally, EOGs from eyes with dilated and undilated pupils were recorded. The light intensity stimulating the eyes with dilated pupils was attenuated 1 log unit. The EOG amplitude ratios displayed no significant difference between the three conditions tested. The comparison of implicit times (time from onset of light exposure to LP) revealed significantly (p < 0.001) shorter values when the recording of the LP was preceded by a dark adaptation of 35 min. The broadening of the curves in DT/LP recordings might be caused by a superposition of a residual dark oscillation on the LP. The recordings from eyes with dilated pupils – stimulated with 1 log unit lower intensity – revealed lower amplitude ratios than the recordings from eyes with undilated pupils.

Keywords:
Electro-oculogram, Light peak, Slow oscillation, Arden ratio, Dark adaptation
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.